TR201909747T4 - Aktarım. - Google Patents

Aktarım. Download PDF

Info

Publication number
TR201909747T4
TR201909747T4 TR2019/09747T TR201909747T TR201909747T4 TR 201909747 T4 TR201909747 T4 TR 201909747T4 TR 2019/09747 T TR2019/09747 T TR 2019/09747T TR 201909747 T TR201909747 T TR 201909747T TR 201909747 T4 TR201909747 T4 TR 201909747T4
Authority
TR
Turkey
Prior art keywords
transfer
charge
methods
delivery
binding
Prior art date
Application number
TR2019/09747T
Other languages
English (en)
Inventor
Dixon James
Shakesheff Kevin
Denning Chris
Original Assignee
Univ Nottingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nottingham filed Critical Univ Nottingham
Publication of TR201909747T4 publication Critical patent/TR201909747T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Bu buluş, protein aktarımı gibi yük moleküllerinin canlı hücrelere aktarımı, özellikle şunları içeren bir hücreye bir yükün aktarılmasına yönelik bir iletim molekülü ile ilgilidir: bir yük-bağlayıcı molekül ve/veya bir yük; hücrenin yüzeyinde GAG?a bağlanabilen bir glikozaminoglikan (GAG) bağlayıcı eleman; ve bir protein aktarım alanı. Aktarım yöntemleri, aktarım için yükün üretilmesine veya modifiye edilmesine yönelik yöntemler, aktarıma yönelik iletim molekülleri ve aktarımı kullanan veya aktarılmış hücreleri kullanan tedaviye yönelik yöntemler sağlanmaktadır.
TR2019/09747T 2013-12-18 2014-12-18 Aktarım. TR201909747T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1322396.1A GB201322396D0 (en) 2013-12-18 2013-12-18 Transduction

Publications (1)

Publication Number Publication Date
TR201909747T4 true TR201909747T4 (tr) 2019-07-22

Family

ID=50071002

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/09747T TR201909747T4 (tr) 2013-12-18 2014-12-18 Aktarım.

Country Status (12)

Country Link
US (2) US10226537B2 (tr)
EP (1) EP3082871B1 (tr)
JP (1) JP6511058B2 (tr)
KR (1) KR20160101083A (tr)
CN (1) CN106102780B (tr)
AU (1) AU2014369443B2 (tr)
CA (1) CA2971291C (tr)
ES (1) ES2733286T3 (tr)
GB (1) GB201322396D0 (tr)
TR (1) TR201909747T4 (tr)
WO (1) WO2015092417A1 (tr)
ZA (1) ZA201604295B (tr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201322396D0 (en) 2013-12-18 2014-02-05 Univ Nottingham Transduction
GB201511158D0 (en) * 2015-06-24 2015-08-05 Univ Nottingham Cell modification and application in therapy
KR101797167B1 (ko) 2016-11-09 2017-11-13 주식회사 바이오셀트란 신규의 프로테인 트랜스덕션 도메인 및 이의 용도
GB201903873D0 (en) 2019-03-21 2019-05-08 Univ Nottingham Enhanced transfection
US20220227886A1 (en) * 2019-05-29 2022-07-21 Albert Einstein College Of Medicine Antibody-based method to identify, purify, and manipulate cell types and processes
KR102479847B1 (ko) * 2020-05-13 2022-12-21 주식회사 젠센 새로운 단백질 수송 도메인, 이를 포함하는 융합 화합물 및 이 융합 화합물을 포함하는 약학 조성물
US20230272024A1 (en) * 2020-07-15 2023-08-31 University Of Florida Research Foundation, Incorporated Fibroblast growth factor 7 peptide
KR102556731B1 (ko) * 2020-09-29 2023-07-21 주식회사 젠센 단백질 수송 도메인, 이를 포함하는 융합 화합물 및 이 융합 화합물을 포함하는 약학 조성물
JP2022059336A (ja) * 2020-10-01 2022-04-13 国立大学法人広島大学 磁性化細胞および磁性化細胞の誘導方法
JP2024505000A (ja) * 2021-01-27 2024-02-02 シーエスティーエス ヘルス ケア インク． 複数のタンパク質の送達のための血小板アルファ顆粒
WO2023041639A2 (fr) * 2021-09-15 2023-03-23 Centre National De La Recherche Scientifique Nanoparticules hybrides
KR102683861B1 (ko) * 2023-04-05 2024-07-11 주식회사 씨지헬스테크 역노화 효과를 나타내는 야마나카 인자의 유전자 전달 효율을 높이는 신규 융합펩타이드 및 이의 용도

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2485250A1 (fr) 1980-06-18 1981-12-24 Commissariat Energie Atomique Cellule photogalvanique, utilisable notamment pour convertir l'energie solaire en energie electrique
US5817789A (en) 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
US6881825B1 (en) 1999-09-01 2005-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Identication of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and virues
US20030104622A1 (en) * 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
FR2805821B1 (fr) * 2000-03-01 2004-01-16 Diatos Sequences d'acides amines facilitant la penetration d'une substance d'interet a l'interieur des cellules et/ou des noyaux cellulaires
EP1174506A1 (en) 2000-06-28 2002-01-23 Stichting Dienst Landbouwkundig Onderzoek C-terminal Erns peptide and analogues thereof
US20020151004A1 (en) 2000-07-24 2002-10-17 Roger Craig Delivery vehicles and methods for using the same
US7049286B2 (en) 2001-08-30 2006-05-23 Diatos, S.A. Insulin conjugates and methods of use thereof
AU2003260668A1 (en) * 2002-04-01 2003-10-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Biological affinity based delivery systems
US20070071677A1 (en) 2003-03-10 2007-03-29 Park Yoon J Non-toxic membrane-translocating peptides
US7329638B2 (en) 2003-04-30 2008-02-12 The Regents Of The University Of Michigan Drug delivery compositions
AU2004247025B8 (en) 2003-05-16 2011-06-30 Acorda Therapeutics, Inc. Fusion proteins for the treatment of CNS
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
JP2008504239A (ja) * 2004-06-24 2008-02-14 ザ ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ 複合体およびその治療的使用
WO2006036410A2 (en) 2004-08-27 2006-04-06 The Regents Of The University Of California Protection from and treatment of prion protein infection
WO2006029078A2 (en) 2004-09-07 2006-03-16 The Regents Of The University Of California Targeting transducible molecules to specific cell types
EP1818395A1 (en) * 2006-02-08 2007-08-15 Diatos Compositions and methods for treating lysosomal storage diseases
US20100221235A1 (en) 2006-02-08 2010-09-02 Diatos Compositions and Methods for Treating Lysosomal Storage Diseases
CA2638915A1 (en) 2006-02-10 2007-08-23 The Regents Of The University Of California Transducible delivery of sirna by dsrna binding domain fusions to ptd/cpps
US8410045B2 (en) 2006-03-30 2013-04-02 Drais Pharmaceuticals, Inc. Camptothecin-peptide conjugates and pharmaceutical compositions containing the same
EP1867661A1 (en) 2006-06-12 2007-12-19 Diatos Compositions and methods for delivering anti-activated ras antibodies into cells
WO2008006064A2 (en) 2006-07-07 2008-01-10 Georgia Tech Research Corporation Biomimetic polymers and uses thereof
JP2010537632A (ja) * 2007-08-29 2010-12-09 タフツ ユニバーシティー 組織及び細胞への核酸、タンパク質、薬物、及びアデノウイルスの送達を向上させるための細胞透過性ペプチドの製造及び使用方法、組成物並びにキット
US8389768B2 (en) 2008-05-19 2013-03-05 The University Of North Carolina At Chapel Hill Methods and compositions comprising novel cationic lipids
EP2147683A1 (en) * 2008-07-25 2010-01-27 DKFZ Deutsches Krebsforschungszentrum Construct and method for the internalization of cargo molecules into a cell
JP5336275B2 (ja) 2009-06-26 2013-11-06 東京ラヂエーター製造株式会社 尿素水タンク
US20110054236A1 (en) 2009-08-25 2011-03-03 The Regents Of The University Of Michigan Compositions and methods for targeting tumors
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011106788A2 (en) 2010-02-26 2011-09-01 Vascular Biosciences, Inc. Car peptide for homing, diagnosis, & targeted therapy for pulmonary and fibrotic disorders
US20120190107A1 (en) 2011-01-26 2012-07-26 Dwayne Bisgrove Enhanced protein transduction
EP2686344A1 (en) 2011-03-16 2014-01-22 Protaffin Biotechnologie AG Fgfr1-based antagonists with improved glycosaminoglycan affinity and methods of using same
WO2013114363A2 (en) 2012-01-30 2013-08-08 Yeda Research And Development Co.Ltd. Antimicrobial agents
JP5918909B2 (ja) 2012-06-25 2016-05-18 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 標的化治療薬
KR101456026B1 (ko) 2012-09-18 2014-11-04 서울대학교산학협력단 종양선택적 투과기능성을 가지는 펩타이드 및 그 용도
US20160031985A1 (en) 2013-03-15 2016-02-04 Katherine S. Bowdish Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
KR101529634B1 (ko) 2013-08-28 2015-06-30 서울대학교산학협력단 역분화 유도를 위한 세포투과성 융합 단백질 및 그 용도
GB201322396D0 (en) 2013-12-18 2014-02-05 Univ Nottingham Transduction

Also Published As

Publication number Publication date
WO2015092417A1 (en) 2015-06-25
JP6511058B2 (ja) 2019-05-08
CA2971291A1 (en) 2015-06-25
AU2014369443B2 (en) 2019-08-01
US10226537B2 (en) 2019-03-12
JP2017501710A (ja) 2017-01-19
KR20160101083A (ko) 2016-08-24
US20190216941A1 (en) 2019-07-18
CN106102780A (zh) 2016-11-09
AU2014369443A1 (en) 2016-07-14
US20170080101A1 (en) 2017-03-23
ZA201604295B (en) 2022-04-28
GB201322396D0 (en) 2014-02-05
CN106102780B (zh) 2020-11-10
CA2971291C (en) 2022-08-30
US11672870B2 (en) 2023-06-13
EP3082871A1 (en) 2016-10-26
EP3082871B1 (en) 2019-05-01
ES2733286T3 (es) 2019-11-28

Similar Documents

Publication Publication Date Title
TR201909747T4 (tr) Aktarım.
CY1120646T1 (el) Προγονικα κυτταρα μεσοδερμικης προελευσης
PH12021550307A1 (en) T Cell Receptor Constructs And Uses Thereof
CY1119518T1 (el) Τροποποιημενα αντιγονα φυματιωσης
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
EA201891212A1 (ru) Адресная дезорганизация клеточного рецептора гкгс
MX2019008346A (es) Receptores de celulas t que se unen a ny-eso-1 y metodos de uso de estos.
PH12015502039B1 (en) Anti-lag-3 binding proteins
NZ758715A (en) Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
MX2016007063A (es) Peptidos terapeuticos.
AR093377A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
CL2015000829A1 (es) Inhibidores de histona desmetilasas
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
CY1119093T1 (el) Ανοσο-ρυθμιστικο προγονικο (imp) κυτταρο
EA201000146A1 (ru) Связующее майларда на основе гидроксимонокарбоновой кислоты
UY33647A (es) ?agentes de unión a cd33?.
UY34254A (es) Proteínas y péptidos modificados.
AR095596A1 (es) Moléculas de unión de cadena única comprendiendo n-terminal abp
EA201500172A1 (ru) Модифицированные полипептиды фактора х и их применение
UY32971A (es) Proteínas de unión al antígeno de la il-23 humana
BR112012018021A2 (pt) antídotos anticoagulantes.
UY35718A (es) Anticuerpos anti-csf-1r: métodos de expresión de los mismos.
CY1123144T1 (el) Επαγωγη καρδιακης αναγεννησης μe microrna
CL2009000862A1 (es) Anticuerpo aislado, derivados o fragmentos aislados del mismo capaz de unirse a la proteina cd151, composición que lo comprende; ácido nucleico que lo codifica, vector y célula huesped que lo comprenden; procedimiento para preparar dicho anticuerpo; util como medicamento para prevenir o tratar el cáncer.
EA201890439A1 (ru) ИММУНООНКОЛОГИЧЕСКАЯ МЕЗОДЕРМАЛЬНАЯ КЛЕТКА-ПРЕДШЕСТВЕННИК (ioMP-КЛЕТКА)